Reply to Verweij et al. [6]

Reginald E. Greene; Haran T. Schlamm; Jörg W. Oestmann; Paul Stark; Christine Durand; Olivier Lortholary; John R. Wingard; Raoul Herbrecht; Patricia Ribaud; Thomas F. Patterson; Peter F. Troke; David W. Denning; John E. Bennett; Ben E. De Pauw; Robert H. Rubin

doi:10.1086/518388

Reply to Verweij et al. [6]

Reginald E. Greene, Haran T. Schlamm, Jörg W. Oestmann, Paul Stark, Christine Durand, Olivier Lortholary, John R. Wingard, Raoul Herbrecht, Patricia Ribaud, Thomas F. Patterson, Peter F. Troke, David W. Denning, John E. Bennett, Ben E. De Pauw, Robert H. Rubin

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1667-1668
Number of pages	2
Journal	Clinical Infectious Diseases
Volume	44
Issue number	12
DOIs	https://doi.org/10.1086/518388
State	Published - Jun 15 2007

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/518388

Cite this

Reply to Verweij et al. [6]. / Greene, Reginald E.; Schlamm, Haran T.; Oestmann, Jörg W.; Stark, Paul; Durand, Christine; Lortholary, Olivier; Wingard, John R.; Herbrecht, Raoul; Ribaud, Patricia; Patterson, Thomas F.; Troke, Peter F.; Denning, David W.; Bennett, John E.; De Pauw, Ben E.; Rubin, Robert H.

In: Clinical Infectious Diseases, Vol. 44, No. 12, 15.06.2007, p. 1667-1668.

Research output: Contribution to journal › Letter › peer-review

Greene, Reginald E. ; Schlamm, Haran T. ; Oestmann, Jörg W. ; Stark, Paul ; Durand, Christine ; Lortholary, Olivier ; Wingard, John R. ; Herbrecht, Raoul ; Ribaud, Patricia ; Patterson, Thomas F. ; Troke, Peter F. ; Denning, David W. ; Bennett, John E. ; De Pauw, Ben E. ; Rubin, Robert H. / Reply to Verweij et al. [6]. In: Clinical Infectious Diseases. 2007 ; Vol. 44, No. 12. pp. 1667-1668.

@article{f060dbcda6304ed3af3ca9aadcb92a35,

title = "Reply to Verweij et al. [6]",

author = "Greene, {Reginald E.} and Schlamm, {Haran T.} and Oestmann, {J{\"o}rg W.} and Paul Stark and Christine Durand and Olivier Lortholary and Wingard, {John R.} and Raoul Herbrecht and Patricia Ribaud and Patterson, {Thomas F.} and Troke, {Peter F.} and Denning, {David W.} and Bennett, {John E.} and {De Pauw}, {Ben E.} and Rubin, {Robert H.}",

note = "Funding Information: Potential conflicts of interest. P.E.V. has received research funding from Pfizer, Gilead Sciences, Merck, Basilea, and Schering-Plough; has been a consultant for Pfizer and Schering-Plough; and has served on the speakers{\textquoteright} bureau for Merck and Schering-Plough. J.P.D. has received research funding from AM-Phama VA and Schering-Plough; has been a consultant for Janssen Pharmaceuticals, Gilead Sciences, and Pfizer; and has served on the speakers{\textquoteright} bureau for Janssen Pharmaceuticals, Gilead Sciences, and Pfizer. L.V.D.: no conflicts. Funding Information: ceived honoraria from Pfizer and Schering-Plough. H.T.S. and P.F.T. are employees of Pfizer. O.L. has served on the speakers{\textquoteright} bureaus of Pfizer, Merck, and Astellas. J.R.W. has served as a consultant and advisor for Pfizer, Merck, Schering-Plough, and Nektar; has received honoraria from Pfizer and Merck; and has received research funding from Pfizer. R.H. has served as a consultant and advisor for Pfizer, Merck, Gilead, and Schering-Plough and has received research funding from Pfizer. P.R. has received honoraria from Pfizer, Merck, and Schering-Plough. T.F.P. has served as a consultant and advisor for Pfizer, Schering-Plough, Astellas, Merck, Affinium, Basilea, Diversa, Eisai, J Uriach, MediciNova, Microbia, Nektar, Rib-X, and Human Genome Sciences; has been on the speakers{\textquoteright} bureau for Pfizer, Schering-Plough, Astellas, and Merck; and has received research funding from Schering-Plough, Astellas, Merck, Enzon, and Pfizer. D.W.D. has received research funding from Pfizer. B.E.dP. has received honoraria from Pfizer and Merck. R.H.R. has served as a consultant and advisor for and has received honoraria from Pfizer and Merck. H.T.S. is a shareholder in Pfizer. J.E.B. is a shareholder in Merck. All other authors: no conflicts",

year = "2007",

month = jun,

day = "15",

doi = "10.1086/518388",

language = "English (US)",

volume = "44",

pages = "1667--1668",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Reply to Verweij et al. [6]

AU - Greene, Reginald E.

AU - Schlamm, Haran T.

AU - Oestmann, Jörg W.

AU - Stark, Paul

AU - Durand, Christine

AU - Lortholary, Olivier

AU - Wingard, John R.

AU - Herbrecht, Raoul

AU - Ribaud, Patricia

AU - Patterson, Thomas F.

AU - Troke, Peter F.

AU - Denning, David W.

AU - Bennett, John E.

AU - De Pauw, Ben E.

AU - Rubin, Robert H.

N1 - Funding Information: Potential conflicts of interest. P.E.V. has received research funding from Pfizer, Gilead Sciences, Merck, Basilea, and Schering-Plough; has been a consultant for Pfizer and Schering-Plough; and has served on the speakers’ bureau for Merck and Schering-Plough. J.P.D. has received research funding from AM-Phama VA and Schering-Plough; has been a consultant for Janssen Pharmaceuticals, Gilead Sciences, and Pfizer; and has served on the speakers’ bureau for Janssen Pharmaceuticals, Gilead Sciences, and Pfizer. L.V.D.: no conflicts. Funding Information: ceived honoraria from Pfizer and Schering-Plough. H.T.S. and P.F.T. are employees of Pfizer. O.L. has served on the speakers’ bureaus of Pfizer, Merck, and Astellas. J.R.W. has served as a consultant and advisor for Pfizer, Merck, Schering-Plough, and Nektar; has received honoraria from Pfizer and Merck; and has received research funding from Pfizer. R.H. has served as a consultant and advisor for Pfizer, Merck, Gilead, and Schering-Plough and has received research funding from Pfizer. P.R. has received honoraria from Pfizer, Merck, and Schering-Plough. T.F.P. has served as a consultant and advisor for Pfizer, Schering-Plough, Astellas, Merck, Affinium, Basilea, Diversa, Eisai, J Uriach, MediciNova, Microbia, Nektar, Rib-X, and Human Genome Sciences; has been on the speakers’ bureau for Pfizer, Schering-Plough, Astellas, and Merck; and has received research funding from Schering-Plough, Astellas, Merck, Enzon, and Pfizer. D.W.D. has received research funding from Pfizer. B.E.dP. has received honoraria from Pfizer and Merck. R.H.R. has served as a consultant and advisor for and has received honoraria from Pfizer and Merck. H.T.S. is a shareholder in Pfizer. J.E.B. is a shareholder in Merck. All other authors: no conflicts

PY - 2007/6/15

Y1 - 2007/6/15

UR - http://www.scopus.com/inward/record.url?scp=34249871675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249871675&partnerID=8YFLogxK

U2 - 10.1086/518388

DO - 10.1086/518388

M3 - Letter

AN - SCOPUS:34249871675

VL - 44

SP - 1667

EP - 1668

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -